Somatostatin receptor expression in parathyroid neoplasms
| Autor: | Eeva Ryhänen, Johanna Louhimo, Caj Haglund, Johanna Arola, Helena Leijon, Sara Storvall, Camilla Schalin-Jäntti |
|---|---|
| Přispěvatelé: | Endokrinologian yksikkö, Department of Medicine, Clinicum, HUS Abdominal Center, University of Helsinki, HUSLAB, Department of Pathology, Department of Surgery, II kirurgian klinikka, University Management |
| Rok vydání: | 2019 |
| Předmět: |
tumor
CARCINOMA Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism somatostatin lcsh:Diseases of the endocrine glands. Clinical endocrinology SUBTYPES hyperparathyroidism 03 medical and health sciences PROGNOSTIC-FACTORS 0302 clinical medicine Endocrinology OCTREOTIDE Internal Medicine medicine Somatostatin receptor 2 parathyroid Somatostatin receptor 1 education education.field_of_study Hyperparathyroidism lcsh:RC648-665 Somatostatin receptor-5 REASSESSMENT Somatostatin receptor business.industry Parathyroid neoplasm Research medicine.disease CANCER TUMORS TRANSLOCATION 3. Good health Parathyroid carcinoma 3121 General medicine internal medicine and other clinical medicine 030220 oncology & carcinogenesis immunohistochemistry Cancer research business hormones hormone substitutes and hormone antagonists Primary hyperparathyroidism |
| Zdroj: | Endocrine Connections, Vol 8, Iss 8, Pp 1213-1223 (2019) Endocrine Connections |
| ISSN: | 2049-3614 |
| Popis: | Introduction Parathyroid carcinoma represents a rare cause of primary hyperparathyroidism. Distinguishing carcinoma from the benign tumors underlying primary hyperparathyroidism remains challenging. The diagnostic criteria for parathyroid carcinoma are local and/or metastatic spreading. Atypical parathyroid adenomas share other histological features with carcinomas but lack invasive growth. Somatostatin receptors are commonly expressed in different neuroendocrine tumors, but whether this also holds for parathyroid tumors remains unknown. Aim Our aim is to examine the immunohistochemical expression of somatostatin receptor 1–5 in parathyroid typical adenomas, atypical adenomas and carcinomas. Methods We used a tissue microarray construct from a nationwide cohort of parathyroid carcinomas (n = 32), age- and gender-matched typical parathyroid adenomas (n = 72) and atypical parathyroid adenomas (n = 27) for immunohistochemistry of somatostatin receptor subtypes 1–5. We separately assessed cytoplasmic, membrane and nuclear expression and also investigated the associations with histological, biochemical and clinical characteristics. Results All parathyroid tumor subgroups expressed somatostatin receptors, although membrane expression appeared negligible. Except for somatostatin receptor 1, expression patterns differed between the three tumor types. Adenomas exhibited the weakest and carcinomas the strongest expression of somatostatin receptor 2, 3, 4 and 5. We observed the largest difference for cytoplasmic somatostatin receptor 5 expression. Conclusions Parathyroid adenomas, atypical adenomas and carcinomas all express somatostatin receptor subtypes 1–5. Somatostatin receptor 5 may serve as a potential tumor marker for malignancy. Studies exploring the role of somatostatin receptor imaging and receptor-specific therapies in patients with parathyroid carcinomas are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|